Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1.
Drug Des Devel Ther
; 15: 5035-5059, 2021.
Article
en En
| MEDLINE
| ID: mdl-34949914
ABSTRACT
INTRODUCTION:
With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1.RESULTS:
A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the anti-apoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the DeferasiroxMcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234.CONCLUSION:
Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Proteínas Reguladoras de la Apoptosis
/
Reposicionamiento de Medicamentos
/
Proteína 1 de la Secuencia de Leucemia de Células Mieloides
/
Deferasirox
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Drug Des Devel Ther
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2021
Tipo del documento:
Article
País de afiliación:
Francia